Anaes SAQs · Malignant hyperthermia
Dantrolene — pharmacology, dose and the calcium-channel-blocker contraindication
The dantrolene pharmacology SAQ — mechanism (direct partial RYR1 antagonist, stops sarcoplasmic-reticulum calcium release), dose (2.5 mg/kg repeat to 10 mg/kg), the laborious traditional vial reconstitution versus Ryanodex, and the dangerous interaction with calcium channel blockers. Anchored to the Krause dantrolene review.
On this page
Study tools
Target exams
ANZCAFRCAABAEDAIC
Prompt
Discuss the pharmacology of dantrolene. Include its mechanism of action, the dose used in a malignant hyperthermia crisis, the practical problems of its traditional formulation, and the one important drug interaction to avoid.
Question
Discuss the pharmacology of dantrolene. Include its mechanism of action, the dose used in a malignant hyperthermia crisis, the practical problems of its traditional formulation, and the one important drug interaction to avoid.
References2ShowHide
- [16]Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene — a review of its pharmacology, therapeutic use and new developments. Anaesthesia, 2004.PMID 15023108
- [8]Glahn KPE, Girard T, Hellblom A, et al. Recognition and management of a malignant hyperthermia crisis: updated 2024 guideline from the European Malignant Hyperthermia Group. British Journal of Anaesthesia, 2025.PMID 39482150